Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

74.15 -1.01 (-1.34%)

Streaming Delayed Price Updated: 2:51 PM EST, Mar 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

The Latest Analyst Ratings For Ionis Pharmaceuticals ↗

July 16, 2024

Via Benzinga

Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts ↗

June 27, 2024

Via Benzinga

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 24, 2024

Via Benzinga

Masters In Trading - Saturday, June 22 ↗

June 22, 2024

In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio.

Via Talk Markets

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗

June 03, 2024

Via Benzinga

Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile ↗

May 31, 2024

Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year.

Via Benzinga

The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals ↗

May 08, 2024

Via Benzinga

The Latest Analyst Ratings For Ionis Pharmaceuticals ↗

April 09, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals ↗

February 22, 2024

Via Benzinga

Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder ↗

May 31, 2024

The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.

Via Benzinga

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another ↗

May 16, 2024

Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.

Via Benzinga

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

May 16, 2024

From Biogen Inc.

Via GlobeNewswire

The 3 Most Undervalued Pharma Stocks to Buy in May 2024 ↗

May 09, 2024

Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks.

Via InvestorPlace

Earnings Scheduled For February 21, 2024 ↗

February 21, 2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

Via Benzinga

Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts ↗

January 18, 2024

Via Benzinga

IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

IONS stock results show that Ionis Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows ↗

March 13, 2024

Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with...

Via Benzinga

Are These 5 Undervalued Stocks Ready to Break Out?

March 08, 2024

Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.

Via MarketBeat

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

March 06, 2024

From Biogen Inc.

Via GlobeNewswire

JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know ↗

February 01, 2024

Via Benzinga

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines ↗

January 31, 2024

Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.

Via Benzinga

Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study ↗

January 22, 2024

Phase 3 OASIS-HAE study results by Ionis Pharmaceuticals Donidalorsen shows remarkable efficacy, safety, and plans for FDA submission.

Via Benzinga

Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

January 08, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs ↗

January 04, 2024

A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...

Via Benzinga

Topics ETFs

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies ↗

December 27, 2023

These future trillion dollar stocks can solidify portfolio growth for long-term investors. Discover the stocks to buy in 2024.

Via InvestorPlace

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗

December 22, 2023

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

Via Benzinga

New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment ↗

December 22, 2023

Friday, FDA approved AstraZeneca

Via Benzinga

Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach ↗

December 19, 2023

Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.